GENFIT
is a France-based late-stage biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of metabolic and inflammatory diseases... Read moreGENFIT
is a France-based late-stage biopharmaceutical company that develops and commercializes novel therapeutics for the treatment of metabolic and inflammatory diseases... Read more
News
Apr 07, 2026
Benzinga
GENFIT: GENFIT Announces Publication of the 2025 Universal Registration Document
Apr 02, 2026
GlobalNewswire
Press Release: GENFIT : GENFIT Reports Full-Year 2025 Financial Results and Provides Corporate Update
Mar 10, 2026
Nasdaq
GENFIT: Genfit Receives FDA Orphan Drug Designation For NTZ In Acute-on-Chronic Liver Failure
Feb 26, 2026
FinanzNachrichten
GENFIT: GENFIT S.A.: GENFIT Reports Fourth Quarter 2025 Financial Information and Provides a Corporate Update
Feb 13, 2026
European Biotechnology
GENFIT: GENFIT to receive $20M milestone from Ipsen as Iqirvo tops $200M in first full year
Jan 07, 2026
Yahoo
GENFIT: GENFIT Announces 2026 Financial Calendar
Jan 06, 2026
MarketScreener
GENFIT: Genfit Reports Promising Results from Phase 1 Study
Jan 06, 2026
Benzinga
GENFIT: GENFIT: Favorable Phase 1 Safety Profile and Strong Anti-Inflammatory Activity for ACLF Lead Asset G1090N
Dec 29, 2025
MarketScreener
GENFIT: Genfit: 683 Capital Partners Surpasses 5% Ownership Threshold
Dec 10, 2025
StreetInsider
Press Release: GENFIT : GENFIT: GNS561 Shows Promising Antitumor Activity in Combination Therapy
GENFIT Competitors
1
2
3
4
5
6
7
8
9
10